Showing 1421-1430 of 20413 results for "".
Predicting Outcomes in IBD with Fecal Biomarkers
https://reachmd.com/programs/gi-insights/predicting-outcomes-in-ibd-with-fecal-biomarkers/32328/Read about recent findings on fecal biomarkers that can help predict complications in patients with inflammatory bowel disease.Improving CRC Screening Uptake: An Integrated Approach
https://reachmd.com/programs/clinicians-roundtable/increase-crc-screening-uptake-integrated/56445/A recent retrospective study evaluated how combining shared decision making and EHR-enabled workflow optimization impacted colorectal cancer (CRC) screening adherence among patients aged 45 and older. Learn more as Dr. Mallik Greene dives into the details and explains how this approach could imprSteroidal vs Nonsteroidal MRAs: Implications for Heart Failure Care
https://reachmd.com/programs/heart-matters/steroidal-vs-nonsteroidal-mras-implications-for-heart-failure-care/54802/Mineralocorticoid receptor antagonists (MRAs) play a key role in heart failure management, with differences between steroidal and nonsteroidal agents having the power to shape treatment decisions. Understanding these pharmacologic distinctions and clinical impacts can help optimize patient outcomesUnderstanding iMCD Through RNA Sequencing
https://reachmd.com/programs/project-oncology/understanding-imcd-through-rna-sequencing/26403/Explore how gene expression in idiopathic multicentric Castleman disease can help improve diagnostic and therapeutic strategies.Managing Psoriasis Flare-Ups: The Influence of Ultra-Processed Foods
https://reachmd.com/programs/spotlight-psoriasis/managing-psoriasis-flare-ups-the-influence-of-ultra-processed-foods/32444/Ultra-processed foods may exacerbate flare-ups in patients with psoriasis. Read about a recent study and its findings on this potential connection.Real-World CDK4/6 Inhibitor Patterns in HR+/HER2– Metastatic Breast Cancer
https://reachmd.com/programs/project-oncology/real-world-cdk46-inhibitor-patterns-in-hrher2-metastatic-breast-cancer/36161/CDK4/6 inhibitors play a central role in the first-line treatment of hormone receptor-positive, HER2-negative (HR+/HER2–) metastatic breast cancer, but how do they perform outside of clinical trials? That’s what a recent real-world study aimed to find out, examining treatment patterns, tolerability,Tailoring Inflammatory Bowel Disease Care: Selection Criteria and Timing
https://reachmd.com/programs/gi-insights/tailoring-inflammatory-bowel-disease-care-selection-criteria-and-timing/35591/As the advanced treatment landscape for inflammatory bowel disease continues to expand, selecting the right therapies has become more complex, with efficacy, safety, patient preferences, disease phenotypes, and more as factors to consider. Learn how to effectively navigate these therapeutic optionsLiving Well with IBD: Proactive Health Maintenance Strategies
https://reachmd.com/programs/gi-insights/living-well-with-ibd-proactive-health-maintenance-strategies/18013/Join us as we explore how we can optimize the health of our patients with IBD using strategies that go beyond the treatment of symptoms and disease.Highlights from VBS 2026: From Care Innovations to Clinician Wellness
https://reachmd.com/programs/eye-on-ocular-health/vbs-2026-innovations-clinician-wellness/56547/The 2026 Vit-Buckle Society (VBS) Annual Meeting featured candid case-based discussions on real-world complications and innovative approaches, as well as sessions dedicated to promoting physician wellness. Catch up on insights from this year's meeting with Dr. Akshay Thomas, a vitreoretinal surgeonImproving Colorectal Cancer Screening Adherence: Advantages of FIT
https://reachmd.com/programs/clinicians-roundtable/improving-colorectal-cancer-screening-adherence-advantages-of-fit/36703/For younger adults needing to get screened for colorectal cancer, fecal immunochemical testing (FIT) may help with initiation and adherence because of its speed, ease, and noninvasiveness. Hear Dr. Theodore Levin discuss FIT and its potential benefits, particularly in younger adults. Dr. Levin is a